Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.

Heroes is a multicentre, national, non-randomized, open-label, phase 2 study. The goal of this clinical trial is to evaluate the feasibility of therapeutic de-escalation in HER2-positive metastatic breast cancer with disease controlled after 2 years of maintenance treatment with anti-HER2 targeted therapy AND ctDNA negative testing. The main question it aims to answer is : • Is it possible to identify patients for whom temporary or permanent discontinuation of treatment is possible without impacting prognosis?

Trial Details

NCT ID
NCT06450314
Phase
PHASE2
Sponsor
UNICANCER
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Discontinuation of the anti-HER2 maintenance therapy
  • Monitoring with signatera test
Locations (sample)
  • Rennes, France|48.11109,-1.67431

Key Eligibility Criteria

  • Patient must have signed a written informed consent prior to any trial specific procedures. When the patient is physically unable to give their wri…
  • Men or women ≥18 years of age;
  • Documented diagnosis of locally advanced inoperable or metastatic histologically-proven HER2-positive breast cancer (HER2-positive is defined as HE…
  • Must have an adequate archival tumor tissue sample available for next-generation sequencing (NGS) analysis by central laboratory, in order to desig…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →